These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 646574)

  • 1. The efficacy of calcifediol in renal osteodystrophy.
    Recker R; Schoenfeld P; Letteri J; Slatopolsky E; Goldsmith R; Brickman A
    Arch Intern Med; 1978 May; 138 Spec No():857-63. PubMed ID: 646574
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
    Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency].
    von Herrath D; Kraft D; Grigoleit HG; Schaefer K
    Dtsch Med Wochenschr; 1973 Jul; 98(28):1379-81. PubMed ID: 4197778
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 6. [1 alpha-hydroxycholecalciferol in treatment of renal osteodystrophy].
    Chalmers TM; Davie MW; Hunter JO; Szaz KF
    J Urol Nephrol (Paris); 1974 Dec; 80(12):981. PubMed ID: 4617778
    [No Abstract]   [Full Text] [Related]  

  • 7. A model for clinical research studies of renal osteodystrophy in children.
    Norman ME; Mazur A; Gruskin AB
    Arch Intern Med; 1978 May; 138 Spec No():866-8. PubMed ID: 646576
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis].
    Albertazzi A; Palmieri PF; Del Rosso G; Spisni C; Evangelista M
    Minerva Nefrol; 1980; 27(4):631-3. PubMed ID: 7254690
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications].
    García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F
    Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095
    [No Abstract]   [Full Text] [Related]  

  • 10. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
    Teitelbaum SL
    Ann Intern Med; 1981 Mar; 94(3):404-5. PubMed ID: 6894359
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis].
    Palmieri P; Albertazzi A; Cappelli P; Di Paolo B
    G Clin Med; 1981 Jul; 62(7):443-60. PubMed ID: 7308629
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.
    Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF
    Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The investigation and treatment of renal osteodystrophy.
    Catto GR; MacLeod M; Pelc B; Kodicek E
    Proc Eur Dial Transplant Assoc; 1975; 11():473-80. PubMed ID: 1197272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement of early renal bone disease with alfacalcidol therapy.
    CMAJ; 1995 Nov; 153(10):1470, 1472. PubMed ID: 7585375
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical picture, diagnosis and therapy of renal osteodystrophy].
    Bombor H
    Z Urol Nephrol; 1977 Aug; 70(8):603-7. PubMed ID: 335702
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of uremic osteodystrophy].
    Fletti C; Docci D; Coli' L; Di Felice A
    G Clin Med; 1981 Apr; 62(4):270-9. PubMed ID: 7021295
    [No Abstract]   [Full Text] [Related]  

  • 18. Long term therapy with 1,25(OH)2D3 in dialysis bone disease.
    Pierides AM; Ward MK; Alvarez-Ude F; Ellis HA; Peart KM; Simpson W; Kerr DN; Norman A
    Proc Eur Dial Transplant Assoc; 1976; 12():237-44. PubMed ID: 935116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of renal rickets with 1 alpha-dydroxy cholecalciferol].
    Beer SI; Vure E; Krispin C; Varon M; Taunus A; Cohen D; Mazor J
    Harefuah; 1978 Jan; 94(1):15-7. PubMed ID: 640496
    [No Abstract]   [Full Text] [Related]  

  • 20. Symptomatic renal osteodystrophy after renal transplantation: treatment with 1-alpha-hydroxycholecalciferol.
    Williams PS; Hillis AN; Carty AJ; Sells RA; Bone JM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2227-8. PubMed ID: 3274500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.